AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04509154 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized treatment.
Description: Face-to-face health education sessions led by nurses and physicians, with the possibility to have access to a non-interactive website with pain management materials from a self-help approach.
Study NCT03045536 — intervention group
Intervention type: DEVICE
Intervention: MML (Fa. ESKA/Orthodynamics)
Description: Classification of complications according to MSTS
Study NCT03367351 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Support
Description: Engagement in peer-led CGM specific discussion boards
Study NCT03116776 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Walnut Shell Glasses Moxibustion
Description: Participants in experimental group will receive 12 sessions of walnut shell glasses moxibustion, each for 30 minutes,3 times per week, and administered over 4 weeks.
Study NCT03116776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium hyaluronate eye drops
Description: One drop for each eye, four times per day for over 4 weeks.
Study NCT02093728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selumetinib
Description: Volunteers will recieve single oral dose of 25mg selumetinib in sequence 1, treatment A
Study NCT03367351 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care - serves as the control group for the treatment arm
Study NCT04394182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: 500 mg/24h, 3 days
Study NCT04394182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam
Description: 4 g / 0.5 g administered every 6-8 hours through a vein (directly into the bloodstream), for 5-14 days. Adjustment to kidney function
Study NCT04394182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Description: prophylactic doses
Study NCT04394182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection
Description: 250mg x 3 boluses
Study NCT02093728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itraconazole
Description: Volunteers will receive oral doses of itraconazole 200 mg twice daily on Day 1 to Day 7 in sequence 1 treatment B:
Study NCT01006486 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anticoagulation clinic
Description: Patients randomized to this arm will be cared at an anticoagulation clinic, with educational measures and standardized procedures related to the use of coumarins.
Study NCT01006486 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard anticoagulation care
Description: Patients randomized to this arm will be cared by their physician, with standard care. No standardized protocol of the use of coumarins will be established.
Study NCT01482403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus
Description: total daily dose of 1000 mg or 1200 mg for 24 weeks
Study NCT01482403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus
Description: total daily dose of 1000 mg or 1200 mg for 48 weeks
Study NCT01482403 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Copegus
Description: total daily dose of 1000 mg or 1200 mg for 48 weeks
Study NCT01482403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: 180 microgram subcutaneous once a week for 24 weeks
Study NCT04394182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: 600mg single dose
Study NCT01482403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: 180 microgram subcutaneous once a week for 48 weeks
Study NCT03156361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDV insulin lispro 100 UNIT/mL
Description: Hepatic Directed Vesicle (HDV) added to commercial insulin lispro
Study NCT03156361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro 100 Units/mL
Description: Sterile Water for Injection added to commercial insulin lispro
Study NCT01482403 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegasys
Description: 180 microgram subcutaneous once a week for 48 weeks
Study NCT04551144 — intervention group
Intervention type: DRUG
Intervention: testosterone cypionate
Description: intramuscular injection every 2 weeks. Dose will be titrated based on blood levels
Study NCT01482403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: boceprevir
Description: 800 mg three times a day for 24 weeks
Study NCT01482403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: boceprevir
Description: 800 mg three times a day for 48 weeks
Study NCT01482403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mericitabine
Description: 1000 mg twice daily for 24 weeks
Study NCT04551144 — intervention group
Intervention type: DRUG
Intervention: Estradiol Valerate
Description: intramuscular injection every week. Dose will be titrated based on blood levels
Study NCT01482403 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mericitabine placebo
Description: mericitabine placebo
Study NCT01482403 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: boceprevir placebo
Description: boceprevir placebo
Study NCT01482403 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: boceprevir
Description: 800 mg three times a day for 44 weeks
Study NCT00892450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin and darifenacin
Description: Participants with overactive bladder will take each medication for 4 weeks.
Study NCT02380157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kaleorid, 750mg (trade name), Potassium chloride (active substance)
Description: 4 weeks treatment with Kaleorid, 750mg, 3 tablets 3 times daily.
Study NCT02116218 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Acupuncture in the Hegu (LI4), Shousanli (LI10), Zusanli (ST36), Yanlinquan (GB34), Taichong (LV3) and Ouch point. Needles would be correctly inserted and manually stimulated until the 'De Qi' sensation is elicited. The needles would stay in place for 15 minutes.
Study NCT02116218 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Vaccaria seed
Description: We put Vaccaria seeds near the acupoints without acupressure as an intervention in control group.
Study NCT02775201 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plantaris release under ultrasound guidance
Description: In patients diagnosed with Achilles tendinopathy the plantaris tendon will be released using a small incision at the medial ankle under ultrasound guidance by a consultant radiologist
Study NCT04280328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciforadenant
Description: 100 mg orally twice daily for 28-day cycles
Study NCT04280328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daratumumab
Description: 16 mg/kg administered intravenously as follows based on 28-day cycles:~* Cycles 1 - 2: Days 1, 8, 15, and 22~* Cycles 3 - 6: Days 1 and 15~* Cycles 7 - 24: Day 1
Study NCT02775201 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plantaris excision surgically
Description: In patients diagnosed with Achilles tendinopathy the plantaris tendon will be excised in theatre by a consultant orthopaedic surgeon
Study NCT02428985 — intervention group
Intervention type: DRUG
Intervention: Riociguat (ADEMPAS, BAY63-2521)
Description: The treatment of Riociguat should comply with the local product information
Study NCT03739840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Padsevonil
Description: Padsevonil in different dosages.
Study NCT02821598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper Limb pattern with flexion - abduction - external rotation
Description: The PNF pattern will be applied three times. Participants will be in supine position under a stretcher, with arms folded and lower limbs in neutral position. In order to induce irradiation for the contralateral lower limb, the left foot sole will be kept in contact with the wall. For EMG recording, the participant will be positioned at the end of the PNF pattern and then the isometric contraction will be solicited. The command used was: do not let me move you.
Study NCT02821598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower Limb pattern with flexion - adduction - external rotation with knee flexion
Description: The PNF pattern will be applied three times. Participants will be in supine position under a stretcher, with arms folded and lower limbs in neutral position. In order to induce irradiation for the contralateral lower limb, the left foot sole will be kept in contact with the wall. For EMG recording, the participant will be positioned at the end of the PNF pattern and then the isometric contraction will be solicited. The command used was: do not let me move you.
Study NCT02821598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower Limb pattern with flexion - abduction - internal rotation with knee flexion
Description: The PNF pattern will be applied three times. Participants will be in supine position under a stretcher, with arms folded and lower limbs in neutral position. In order to induce irradiation for the contralateral lower limb, the left foot sole will be kept in contact with the wall. For EMG recording, the participant will be positioned at the end of the PNF pattern and then the isometric contraction will be solicited. The command used was: do not let me move you.
Study NCT02821598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifting to the right
Description: The PNF pattern will be applied three times. Participants will be in supine position under a stretcher, with arms folded and lower limbs in neutral position. In order to induce irradiation for the contralateral lower limb, the left foot sole will be kept in contact with the wall. For EMG recording, the participant will be positioned at the end of the PNF pattern and then the isometric contraction will be solicited. The command used was: do not let me move you.
Study NCT02821598 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sit to Stand
Description: Subjects will be sitting on a chair without armrests with ankles positioned at approximately 10 degrees of dorsiflexion. Knees will be kept at approximately 100 degrees of flexion. During the task, the participant will be instructed to stand from the sitting position while keeping their arms crossed over the chest. The examiner will give the command ready - set - go. The task will be performed three times.
Study NCT01827410 — intervention group
Intervention type: PROCEDURE
Intervention: Ventral hernia repair
Study NCT01153854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Racecadotril
Description: oral racecadotril (1.5mg./Kg./t.i.d. doe 5 days) in double blind assigned.
Study NCT01153854 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo groups
Description: Placebo with feature color, appearance and tase similar to racecadotril t.i.d. for 5 days
Study NCT05218564 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen Therapy
Description: During the 6 Minute Walking Test (6MWT), the participant will be required to walk as fast as possible on a flat, straight surface on the ward (e.g. corridor) in six minutes, including as many breaks as he/she deems necessary. The performance of this test will be monitored continuously by a Respiratory Physiotherapist and will include the presence of a Physician, who will be ready to assist as needed. The sequence of use of compressed medical air and oxygen used during the 6MWT in the first group will then be characterised as follows: ABC (A=Baseline, B=Air, C=Oxygen). The sequence of the second group will be characterised as follows: ACB (A=Baseline, B=Air, C=Oxygen).
Study NCT05218564 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compressed Medical Air
Description: During the 6 Minute Walking Test (6MWT), the participant will be required to walk as fast as possible on a flat, straight surface on the ward (e.g. corridor) in six minutes, including as many breaks as he/she deems necessary. The performance of this test will be monitored continuously by a Respiratory Physiotherapist and will include the presence of a Physician, who will be ready to assist as needed. The sequence of use of compressed medical air and oxygen used during the 6MWT in the first group will then be characterised as follows: ABC (A=Baseline, B=Air, C=Oxygen). The sequence of the second group will be characterised as follows: ACB (A=Baseline, B=Air, C=Oxygen).
Study NCT04857450 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Etomidate
Description: Received Etomidate 0.2 mg/kg IV over 30 seconds, followed by Etomidate 0.05 mg/kg IV and repeated when needed.
Study NCT04857450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine Hydrochloride
Description: Received Ketamine 0.5 mg/kg IV over 30 seconds then Etomidate 0.1 mg/kg IV over 30 seconds, followed by 0.05 mg/kg IV and repeated when needed.
Study NCT03569423 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol assisted photorefractive keratectomy
Description: ablations were performed with the Schwind Amaris excimer LASER 750S. Paired student's t-tests and Mann-Whitney tests were used for statistical analysis.
Study NCT03569423 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alcohol assisted photorefractive keratectomy
Description: ablations were performed with the Schwind Amaris excimer LASER 750S. Paired student's t-tests and Mann-Whitney tests were used for statistical analysis.
Study NCT06284928 — intervention group
Intervention type: OTHER
Intervention: Gut Microbiota Analysis
Description: This refers to the procedure of collecting fecal samples from both the hypertension group and the control group, followed by analyzing these samples to assess and compare the gut microbiota composition using methods like gene sequencing.
Study NCT01455428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyrica (pregabalin)
Description: Capsule, 300 mg/d, BID, 8 weeks treatment
Study NCT01455428 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, 300 mg/d, BID, 8 weeks treatment
Study NCT01685294 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group IPT for Depression + TAU
Description: Interpersonal psychotherapy (IPT) will be administered in 20 group 90-minute sessions over 10 weeks and 4 individual sessions (before group starts, in the middle of the group, at the end of the group, and one month after the group ends). These sessions will focus on improving your relationships with others, building healthy relationships, setting goals, and increasing coping skills. Additionally, participants will receive standard prison mental health treatment, individual therapy, medication, etc.
Study NCT01187797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emotional stimulation
Description: Increase of the physical correlates of an emotion
Study NCT03739840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be provided matching padsevonil.
Study NCT03975972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational Therapy Based Literacy Intervention
Description: Use of an occupational therapy-based literacy intervention that utilizes student interest to guide a prescriptive literacy intervention. Addressing reading as an occupation and making the necessary modifications to the literacy task to allows for increased engagement in the task. Increased engagement in literacy tasks, allows for opportunities to work on literacy deficit areas to address proficiency with reading ability.
Study NCT01970579 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel coated balloon
Description: * Treatment of target lesion with study balloon (coated). Diameter of treatment balloon = RVD~* Each study balloon must only be used once (except postdilatation is necessary which may be done with the same balloon used for the initial dilatation)~* Treatment balloon must be 20 mm longer than lesion length (to assure balloon overlap of 10 mm proximal and distal to lesion)~* If two treatment balloons are necessary overlap between the balloon must be 10 mm~* Inflation pressure 7-10 atm~* Intraluminal defects or haziness should be treated with additional inflations and/or aggressive anti-platelet agents or bailout stenting
Study NCT01970579 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: uncoated PTA catheter
Description: * Treatment of target lesion with study balloon (uncoated). Diameter of treatment balloon = RVD~* Each study balloon must only be used once (except postdilatation is necessary which may be done with the same balloon used for the initial dilatation)~* Treatment balloon must be 20 mm longer than lesion length (to assure balloon overlap of 10 mm proximal and distal to lesion)~* If two treatment balloons are necessary overlap between the balloon must be 10 mm~* Inflation pressure 7-10 atm~* Intraluminal defects or haziness should be treated with additional inflations and/or aggressive anti-platelet agents or bailout stenting.
Study NCT02242071 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell
Description: intrathecal autologous bone marrow mononuclear cell transplantation
Study NCT03002987 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Pregnancy policy
Description: Education (3 hours) of leaders in how to implement Active pregnancy policy at their departments/work places
Study NCT05284188 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open or arthroscopic Modified Broström operation
Description: Patients with CLAI and GJL were randomly allocated to accept the open or arthroscopic Modified Broström operation.
Study NCT00372567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: 37.5 mg daily
Study NCT02093728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itraconazole
Description: Volunteers will recieve a single morning dose of 200mg itraconazole on Day 8 and twice daily doses of 200mg itraconazole on Day 8 to Day 11; sequence 1 treatment C.
Study NCT02093728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selumetinib
Description: Volunteers willl recieve a single oral dose of 25 mg selumetinib (4 hours fasted state) on Day 8; sequence 1 treatment C.
Study NCT02093728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selumetinib
Description: Volunteers will recieve single oral dose of 25mg selumetinib in sequence 2, treatment A.
Study NCT02380157 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 weeks treatment with Placebo tablets, 3 tablets 3 times daily.
Study NCT00395447 — intervention group
Intervention type: PROCEDURE
Intervention: Straight-forward Device Replacement
Study NCT00372567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imatinib mesylate
Description: 800mg daily
Study NCT02093728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluconazole
Description: Volunteers will recieve a single dose of 400 mg fluconazole on Day 1 and daily doses of 200 mg fluconazole on Day 2 to Day 7; sequence 2 treatment D.
Study NCT02093728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluconazole
Description: Volunteers will receive a morning dose of 200mg fluconazole on Day 8 and daily doses of 200mg fluconazole on Day 8 to Day 11; sequence 2 treatment E
Study NCT02093728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selumetinib
Description: Volunteers will receive a single dose of 25mg selumetinib (4 hours fasted state) on Day 8; sequence 2 treatment E
Study NCT04233060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS3005
Description: CS3005 will be orally administrated twice daily (BID) until PD, unacceptable toxicity, withdrawal of informed consent, or until maximum treatment duration per protocol (2 years)
Study NCT00395447 — intervention group
Intervention type: PROCEDURE
Intervention: Device Replacement with Upgrade
Study NCT03194932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be given as oral tablets, which are intended to be swallowed intact and may not to be crushed or otherwise altered for administration, or as an oral suspension for patients who cannot swallow tablets.
Study NCT03194932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given intravenously (IV) or intrathecally (IT).
Study NCT03194932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Given IV.
Study NCT03194932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Triple Therapy
Description: Given IT.
Study NCT03194932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV.
Study NCT02174445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Imatinib, 400 to 800 mg p.o., daily
Study NCT02174445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilotinib
Description: 300mg p.o., twice-daily
Study NCT03985657 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Continuous positive airway pressure (CPAP). Room air at pressures between 6-8 centimeters of water (cmH2O) delivered via heated humidified tubing and a nasal mask.
Study NCT03985657 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Continuous positive airway pressure (CPAP). Room air at pressures between 6-8 centimeters of water (cmH2O) delivered via heated humidified tubing and a nasal mask.